摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

对甲苯甲酰肼 | 3619-22-5

中文名称
对甲苯甲酰肼
中文别名
对甲苯肼
英文名称
p-toluic hydrazide
英文别名
p-toluohydrazide;4-methylbenzohydrazide;4-methylbenzoyl hydrazide
对甲苯甲酰肼化学式
CAS
3619-22-5
化学式
C8H10N2O
mdl
MFCD00007607
分子量
150.18
InChiKey
MFFVZXOPRXMVET-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    116-118 °C (lit.)
  • 沸点:
    271.72°C (rough estimate)
  • 密度:
    1.1392 (rough estimate)
  • 最大波长(λmax):
    198nm(MeOH)(lit.)
  • 稳定性/保质期:

    在常温常压下保持稳定

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    55.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xn
  • 安全说明:
    S24/25
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2928000090
  • 危险品运输编号:
    NONH for all modes of transport
  • 危险性防范说明:
    P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    请将药品存放在避光、通风干燥的地方,并密封保存。

SDS

SDS:8df52c2ec8b8370bac416ad1610d6783
查看
Name: P-Toluic Hydrazide 98% Material Safety Data Sheet
Synonym: None Known
CAS: 3619-22-5
Section 1 - Chemical Product MSDS Name:P-Toluic Hydrazide 98% Material Safety Data Sheet
Synonym:None Known

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
3619-22-5 P-Toluic Hydrazide 98% 222-815-2
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3619-22-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 116.00 - 118.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H10N2O
Molecular Weight: 150.18

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3619-22-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
P-Toluic Hydrazide - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 3619-22-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3619-22-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3619-22-5 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

  • 作为反应物:
    描述:
    对甲苯甲酰肼lead(IV) acetate 作用下, 以 二氯甲烷氯仿 为溶剂, 反应 83.0h, 生成 对甲基苯甲酸乙酯
    参考文献:
    名称:
    Stephanidou-Stephanatou, J., Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 845 - 853
    摘要:
    DOI:
  • 作为产物:
    描述:
    对甲基苯甲酸乙酯一水合肼 作用下, 反应 2.0h, 生成 对甲苯甲酰肼
    参考文献:
    名称:
    3-取代(6-[(E)-2-(1-苯并呋喃-2-基)乙烯基][1,2,4]三唑并[3,4-b][1,3,4]噻二唑的合成
    摘要:
    已经研究了 (2E)-3-(1-benzofuran-2-yl)-2-propenoic acid 与 4-amino-5-R-1,2,4-triazole-3-thioles 的反应。已确定 6-[(E)-2-(1-benzofuran-2-yl)ethenyl][1,2,4]triazolo[3,4-b][1,3,4] 噻二唑是杂环化的结果。
    DOI:
    10.1080/10426500701557310
点击查看最新优质反应信息

文献信息

  • Synthesis, Structure, Chemical Stability, and In Vitro Cytotoxic Properties of Novel Quinoline-3-Carbaldehyde Hydrazones Bearing a 1,2,4-Triazole or Benzotriazole Moiety
    作者:Martyna Korcz、Franciszek Sączewski、Patrick Bednarski、Anita Kornicka
    DOI:10.3390/molecules23061497
    日期:——
    -(pyridin-2-yl)hydrazonomethyl]quinoline (5e) showed a cytostatic effect on the cancer cell lines, whereas N′-[(2-(1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-benzohydrazide (7a) and N′-[(2-1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-naphthalene-2-sulfonohydrazide (9h) exhibited selective activity against the pancreas cancer DAN-G and cervical cancer SISO cell lines. Based on the determined IC50
    制备了在 2 位带有 1,2,4-三唑或苯并三唑环的新型喹啉-3-甲醛腙(系列 1)、酰基腙(系列 2)和芳基磺酰腙(系列 3)的小型文库,其特征在于分析以及红外、核磁共振和质谱,然后对三种人类肿瘤细胞系DAN-G、LCLC-103H 和 SISO 进行体外细胞毒性研究。一般来说,被 1,2,4-三唑环取代的化合物 4、6 和 8 被证明是无活性的,而含苯并三唑的喹啉 5、7 和 9 则引起显着的癌细胞生长抑制作用,其 IC50 值在范围为 1.23⁻7.39 µM。最有效的 2-(1H-苯并三唑-1-基)-3-[2-(吡啶-2-基)亚基甲基]喹啉 (5e) 对癌细胞系显示出细胞抑制作用,而 N'-[(2 -(1H-苯并三唑-1-基)喹啉-3-基)亚甲基]-苯并酰(7a)和N'-[(2-1H-苯并三唑-1-基)喹啉-3-基)亚甲基]-- 2-磺酰 (9h) 对胰腺癌 DAN-G 和宫颈癌
  • Degenerate nonlinear absorption and optical power limiting properties of asymmetrically substituted stilbenoid chromophoresElectronic supplementary information (ESI) available: Experimental details. See http://www.rsc.org/suppdata/jm/b3/b313185h/
    作者:Tzu-Chau Lin、Guang S. He、Paras N. Prasad、Loon-Seng Tan
    DOI:10.1039/b313185h
    日期:——
    Two-photon absorption (2PA) spectra (650–1000 nm) of a series of model chromophores were measured via a newly developed nonlinear absorption spectral technique based on a single and powerful femtosecond white-light continuum beam. The experimental results suggested that when either an electron-donor or an electron-acceptor was attached to a trans-stilbene at a para-position, an enhancement in molecular two-photon absorptivity was observed in both cases, particularly in the 650–800 nm region. However, the push–pull chromophores with both the donor and acceptor groups showed larger overall two-photon absorption cross-sections within the studied spectral region as compared to their mono-substituted analogues. The combined results of the solvent effect and the 1H-NMR studies indicated that stronger acceptors produce a more efficient intramolecular charge transfer character upon excitation, leading to increased molecular two-photon responses in this model-compound set. A fairly good 2PA based optical power limiting behavior from one of the model chromophores is also demonstrated.
    通过一种基于单个强飞秒白光连续波束的新型非线性吸收光谱技术,测定了系列模型染料在650-1000 nm范围内的双光子吸收(2PA)光谱。实验结果表明,当电子供体或电子受体分别连接到反式-均二苯代乙烯的邻位时,两种情况下都观察到分子双光子吸收性的增强,尤其是在650-800 nm区域。然而,与单取代的类似物相比,同时含有供体和受体基团的推-拉型染料在整个研究光谱范围内表现出更大的双光子吸收截面。溶剂效应和1H-NMR研究的联合结果表明,更强的受体在激发时产生更有效的分子内电荷转移特性,导致该模型化合物系列中的分子双光子响应增强。其中一种模型染料的相当好的2PA基光学功率限制行为也被展示。
  • Studies in the triazine series including a new synthesis of 1:2:4-triazines
    作者:P.V. Laakso、R. Robinson、H.P. Vandrewala
    DOI:10.1016/0040-4020(57)85014-5
    日期:1957.1
    mono-aroylhydrazones of benzil are cyclised by ammonium acetate in hot acetic acid to tri-substituted-1:2:4-triazines. The yield is favourable and it is not necessary, or even advantageous, to isolate the presumed intermediates. The new synthesis has been applied to a sufficient range of examples to establish its status as a general method. In the case of phenanthraquinone the reaction took a more complex course and
    通过乙酸铵在热乙酸中将苯甲酰的单芳酰基hydr环化为三取代的1:2:4-三嗪。产率是有利的,分离假定的中间体不是必需的,甚至是不利的。新的合成方法已应用于足够多的实例中,以确立其作为一般方法的地位。在菲醌的情况下,反应过程更为复杂,可能涉及两个二酮分子。
  • Design and optimization of N-acylhydrazone pyrimidine derivatives as E. coli PDHc E1 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study
    作者:Haifeng He、Hongying Xia、Qin Xia、Yanliang Ren、Hongwu He
    DOI:10.1016/j.bmc.2017.08.038
    日期:2017.10
    binding site of Escherichia coli (E. coli) pyruvate dehydrogenase multienzyme complex E1 (PDHc E1), a series of novel ‘open-chain’ classes of ThDP analogs A, B, and C with N-acylhydrazone moieties was designed and synthesized to explore their activities against E. coli PHDc E1 in vitro and their inhibitory activity against microbial diseases were further evaluated in vivo. As a result, A1–23 exhibited moderate
    通过靶向胺二磷酸(THDP)结合位点的大肠杆菌(大肠杆菌)丙酮酸脱氢酶多酶复合物E1(PDHC E1),一系列的THDP小说“开链”类的类似物甲,乙,和Ç与ñ -设计并合成了酰基to部分,以探讨它们在体外对大肠杆菌PHDc E1的活性,并在体内进一步评价其对微生物疾病的抑制作用。结果,A1 – 23对大肠杆菌PDHc E1表现出了中度到强效的抑制活性(IC 50 = 0.15–23.55μM)。有效的抑制剂A13,A14,A15,C2具有很强的抑制活性,对大肠杆菌PDHc E1的IC 50值为0.60、0.15、0.39和0.34μM,并且在微生物和哺乳动物之间具有良好的酶选择性抑制作用。特别是,最有效的抑制剂A14可以控制99.37%的米地黄单胞菌(Xanthimonas oryzae pv)。Oryzae。此外,化合物A14在大肠杆菌中的结合特征对PDHc E1进行了研究,以通过分子
  • Synthesis and biological evaluation of novel disulfides incorporating 1,3,4-thiadiazole scaffold as promising antitumor agents
    作者:Sha Li、Hai-Xin Wang、Hai-Ying Liu、Fen Jing、Xiao-Yun Fu、Cai-Wen Li、Yan-Ping Shi、Bao-Quan Chen
    DOI:10.1007/s00044-019-02389-3
    日期:2019.9
    and A549 lines. Bioassay indicated that some compounds showed stronger antitumor effects than reference drugs PX-12 and 5-fluorouracil. Among these screened compounds, compound 7h showed excellent biological activities in inhibiting SMMC-7721 cell proliferation with IC50 at 1.93 ± 0.08 μM. Compounds 7k and 7i manifested highly effective growth inhibitory activity versus MCF-7 cells, with IC50 at 3.04 ± 0
    在本研究中,制备了十四个含二基的2,5-二取代的1,3,4-噻二唑生物。通过IR,NMR,MS和元素分析鉴定了所得化合物7a – 7n。使用针对SMMC-7721,MCF-7和A549品系的标准CCK-8分析法研究了它们的体外抗增殖特性。生物测定表明,某些化合物显示出比参考药物PX-12和5-尿嘧啶更强的抗肿瘤作用。在这些筛选出的化合物中,化合物7h以1.93±0.08μM的IC 50抑制SMMC-7721细胞增殖具有优异的生物学活性。化合物7k和7i与MCF-7细胞相比,具有明显的高效生长抑制活性,IC 50分别为3.04±0.09和3.54±0.17μM。对于A549细胞,发现化合物7m具有最高的抗肿瘤效力,IC 50为3.67±0.13μM。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫